NCT07168902

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

A Phase 2 Evaluation of the Safety, Ocular Tolerability, and Efficacy of Topical Ophthalmic BL1107 Versus Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 228 (estimated)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension

Detailed description

This study will evaluate the safety and efficacy of BL1107 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This is a randomized, double-masked, parallel comparison to evaluate two concentrations of BL1107 in both eyes compared with timolol 0.5% for 28 days.

Conditions

• Glaucoma

Interventions

Type	Name	Description
DRUG	BL1107 Low dose	Dosed twice daily for 28 days.
DRUG	BL1107 High dose	Dosed twice daily for 28 days.
DRUG	Timolol maleate 0.5%	Dosed twice daily for 28 days.

Timeline

• Start date: 2025-10-24
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2025-09-11
• Last updated: 2026-03-31

Locations

14 sites across 1 country: United States

Regulatory

• FDA-regulated drug study